Substance
ID:74106
Names and Identifiers
IUPAC Traditional name
methyl N-[(1S)-1-{N'-[(2S,3S)-2-hydroxy-3-[(2S)-2-[(methoxycarbonyl)amino]-3,3-bis(2H3)methyl(4,4,4-2H3)butanamido]-4-phenylbutyl]-N'-{[4-(pyridin-2-yl)phenyl]methyl}hydrazinecarbonyl}-2,2-dimethylpropyl]carbamate
IUPAC name
methyl N-[(1S)-1-{N'-[(2S,3S)-2-hydroxy-3-[(2S)-2-[(methoxycarbonyl)amino]-3,3-bis(2H3)methyl(4,4,4-2H3)butanamido]-4-phenylbutyl]-N'-{[4-(pyridin-2-yl)phenyl]methyl}hydrazinecarbonyl}-2,2-dimethylpropyl]carbamate
Synonyms
Deuterated Atazanivir-D3-2
Registration numbers
CAS Number
Properties
Safety Information
Storage Condition
-20°C
Molecule Details
Research Area
Description
Infection
Biological Activity
Description
Atazanivir-D3-2 is a azapeptide derivative and inhibits HIV protease.
Targets
HIV protease
IC50
In Vitro
Atazanivir-D3-2 is an azapeptide derivative and a HIV protease inhibitor. Atazanivir-D3-2 is a deuterium-containing agent. [1] Atazanivir-D3-2 displays a shorter half life than atazanavir, as well as Atazanivir-D3-1 and Atazanivir-D3-3. Atazanavir sulfate prevents the formation of mature HIV virions in HIV-1 infected cells by selectively inhibiting the virus-specific processing of certain polyproteins (viral Gag and Gag-Pol). [1] Atazanavir sulfate is currently approved for the treatment of HIV infection. Atazanavir is contraindicated for co-administration with medicines that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. Due to inhibitory effects of atazanavir on CYP3A, CYP2C8, and UGTIAl, caution is advised when prescribing. Common adverse events associated with atazanavir include hyperbilirubinemia, rash, nausea, headache, mid jaundice/sclcral icterus.[1]
In Vivo
Clinical Trials
Features
Molecular Spectra
No Data Available
Click here to submit data
References
• Harbeson, S.L., et al. Eur. Pat. Appl. 2008, 59 pp. EP 2003120 A1 20081217.